WGU D124 FNP OSCE SOAP Note & Practice Exam 2026/2027
Verified Answers & Explanations (GRADED A+)
This comprehensive study package provides a detailed blueprint of the
WGU D124 Midterm OSCE SOAP note focusing on Diabetes Mellitus and
Dyslipidemia management. It includes meticulously formatted multiple-
choice questions complete with verified, updated answers and in-depth
rationales tailored for high-scoring clinical reasoning. Designed for
maximum utility, this resource serves as the ultimate preparation tool for
mastering family nurse practitioner diagnostic documentation and clinical
guidelines.
Question 1
A 54-year-old male with type 2 diabetes mellitus presents for a routine
follow-up. His latest lipid panel reveals an LDL cholesterol level of 130
mg/dL. He has no history of clinical atherosclerotic cardiovascular
disease (ASCVD), and his 10-year ASCVD risk is calculated at 8.5%.
According to the American Diabetes Association (ADA) guidelines, what is
the most appropriate initial management for his dyslipidemia?
A) Lifestyle modifications alone for 3 months
B) Initiate low-intensity statin therapy
C) Initiate moderate-intensity statin therapy
D) Initiate high-intensity statin therapy
,ANSWER: C) Initiate moderate-intensity statin therapy
EXPLANATION: For patients aged 40–75 years with diabetes mellitus
and without established clinical ASCVD, the ADA guidelines
recommend initiating at least a moderate-intensity statin regardless
of the baseline LDL level to reduce cardiovascular risk. Option A is
incorrect because lifestyle modifications alone are insufficient for
diabetic patients in this age bracket. Option B is incorrect because
low-intensity statins are generally not recommended as standard
first-line preventative therapy in diabetes. Option D is incorrect
because high-intensity statins are typically reserved for diabetic
patients with multiple ASCVD risk factors or a 10-year risk score ≥
20%.
Question 2
During a comprehensive diabetic foot exam on a 62-year-old female
patient, the nurse practitioner utilizes a 10-g monofilament. Loss of
protective sensation (LOPS) is noted at 4 out of 10 tested sites. Which of
the following is the most appropriate diagnostic conclusion and
subsequent clinical management plan?
A) Peripheral arterial disease; refer to vascular surgery immediately
B) Diabetic peripheral neuropathy; implement daily self-foot inspections
and prescribe a rigid therapeutic shoe insert
C) Diabetic peripheral neuropathy; educate on daily foot inspection, check
footwear, and schedule a podiatry referral
,D) Normal age-related sensory decline; reassure the patient and retest in
2 years
ANSWER: C) Diabetic peripheral neuropathy; educate on daily foot
inspection, check footwear, and schedule a podiatry referral
EXPLANATION: Inability to feel the 10-g monofilament at one or more
sites indicates loss of protective sensation (LOPS), which confirms
diabetic peripheral neuropathy. Management focuses on patient
empowerment through daily visual self-inspections, evaluating
current footwear for friction points, and establishing a professional
podiatry baseline. Option A is incorrect because monofilament
testing evaluates neurological function, not arterial patency. Option
B is incorrect because therapeutic inserts are not universally
mandated unless severe structural deformities exist. Option D is
incorrect because LOPS is a pathological complication of diabetes,
not benign aging.
Question 3
A 48-year-old female patient with a history of type 2 diabetes mellitus and
hypertension presents with an estimated glomerular filtration rate (eGFR)
of 52 mL/min/1.73 m² and a urine albumin-to-creatinine ratio (UACR) of
180 mg/g. Which class of antihyperglycemic medication provides the dual
benefit of glycemic control and direct renal preservation for this patient?
A) Sulfonylureas (e.g., Glipizide)
B) DPP-4 inhibitors (e.g., Sitagliptin)
, C) SGLT2 inhibitors (e.g., Empagliflozin)
D) Thiazolidinediones (e.g., Pioglitazone)
ANSWER: C) SGLT2 inhibitors (e.g., Empagliflozin)
EXPLANATION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
have demonstrated robust clinical evidence in slowing the
progression of diabetic kidney disease (DKD), reducing
macroalbuminuria, and lowering the risk of a significant eGFR
decline. They are strongly recommended for patients with type 2
diabetes and chronic kidney disease with albuminuria. Options A, B,
and D do not offer verified, direct secondary renal protective
benefits or independent reduction of UACR progression.
Question 4
A 39-year-old male patient presents to the clinic with yellowish, plaque-
like cutaneous lesions located over his Achilles tendons and extensor
surfaces of his elbows. His fasting lipid panel reveals a total cholesterol
of 340 mg/g and an LDL-C of 250 mg/dL. These physical presentation
markers are most pathognomonic for which underlying medical
condition?
A) Acute pancreatitis
B) Familial hypercholesterolemia
C) Diabetic dermopathy
D) Severe hypertriglyceridemia
Verified Answers & Explanations (GRADED A+)
This comprehensive study package provides a detailed blueprint of the
WGU D124 Midterm OSCE SOAP note focusing on Diabetes Mellitus and
Dyslipidemia management. It includes meticulously formatted multiple-
choice questions complete with verified, updated answers and in-depth
rationales tailored for high-scoring clinical reasoning. Designed for
maximum utility, this resource serves as the ultimate preparation tool for
mastering family nurse practitioner diagnostic documentation and clinical
guidelines.
Question 1
A 54-year-old male with type 2 diabetes mellitus presents for a routine
follow-up. His latest lipid panel reveals an LDL cholesterol level of 130
mg/dL. He has no history of clinical atherosclerotic cardiovascular
disease (ASCVD), and his 10-year ASCVD risk is calculated at 8.5%.
According to the American Diabetes Association (ADA) guidelines, what is
the most appropriate initial management for his dyslipidemia?
A) Lifestyle modifications alone for 3 months
B) Initiate low-intensity statin therapy
C) Initiate moderate-intensity statin therapy
D) Initiate high-intensity statin therapy
,ANSWER: C) Initiate moderate-intensity statin therapy
EXPLANATION: For patients aged 40–75 years with diabetes mellitus
and without established clinical ASCVD, the ADA guidelines
recommend initiating at least a moderate-intensity statin regardless
of the baseline LDL level to reduce cardiovascular risk. Option A is
incorrect because lifestyle modifications alone are insufficient for
diabetic patients in this age bracket. Option B is incorrect because
low-intensity statins are generally not recommended as standard
first-line preventative therapy in diabetes. Option D is incorrect
because high-intensity statins are typically reserved for diabetic
patients with multiple ASCVD risk factors or a 10-year risk score ≥
20%.
Question 2
During a comprehensive diabetic foot exam on a 62-year-old female
patient, the nurse practitioner utilizes a 10-g monofilament. Loss of
protective sensation (LOPS) is noted at 4 out of 10 tested sites. Which of
the following is the most appropriate diagnostic conclusion and
subsequent clinical management plan?
A) Peripheral arterial disease; refer to vascular surgery immediately
B) Diabetic peripheral neuropathy; implement daily self-foot inspections
and prescribe a rigid therapeutic shoe insert
C) Diabetic peripheral neuropathy; educate on daily foot inspection, check
footwear, and schedule a podiatry referral
,D) Normal age-related sensory decline; reassure the patient and retest in
2 years
ANSWER: C) Diabetic peripheral neuropathy; educate on daily foot
inspection, check footwear, and schedule a podiatry referral
EXPLANATION: Inability to feel the 10-g monofilament at one or more
sites indicates loss of protective sensation (LOPS), which confirms
diabetic peripheral neuropathy. Management focuses on patient
empowerment through daily visual self-inspections, evaluating
current footwear for friction points, and establishing a professional
podiatry baseline. Option A is incorrect because monofilament
testing evaluates neurological function, not arterial patency. Option
B is incorrect because therapeutic inserts are not universally
mandated unless severe structural deformities exist. Option D is
incorrect because LOPS is a pathological complication of diabetes,
not benign aging.
Question 3
A 48-year-old female patient with a history of type 2 diabetes mellitus and
hypertension presents with an estimated glomerular filtration rate (eGFR)
of 52 mL/min/1.73 m² and a urine albumin-to-creatinine ratio (UACR) of
180 mg/g. Which class of antihyperglycemic medication provides the dual
benefit of glycemic control and direct renal preservation for this patient?
A) Sulfonylureas (e.g., Glipizide)
B) DPP-4 inhibitors (e.g., Sitagliptin)
, C) SGLT2 inhibitors (e.g., Empagliflozin)
D) Thiazolidinediones (e.g., Pioglitazone)
ANSWER: C) SGLT2 inhibitors (e.g., Empagliflozin)
EXPLANATION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
have demonstrated robust clinical evidence in slowing the
progression of diabetic kidney disease (DKD), reducing
macroalbuminuria, and lowering the risk of a significant eGFR
decline. They are strongly recommended for patients with type 2
diabetes and chronic kidney disease with albuminuria. Options A, B,
and D do not offer verified, direct secondary renal protective
benefits or independent reduction of UACR progression.
Question 4
A 39-year-old male patient presents to the clinic with yellowish, plaque-
like cutaneous lesions located over his Achilles tendons and extensor
surfaces of his elbows. His fasting lipid panel reveals a total cholesterol
of 340 mg/g and an LDL-C of 250 mg/dL. These physical presentation
markers are most pathognomonic for which underlying medical
condition?
A) Acute pancreatitis
B) Familial hypercholesterolemia
C) Diabetic dermopathy
D) Severe hypertriglyceridemia
